Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · regulatory

FDA Approves Pluvicto for Earlier Use in Prostate Cancer

3 August 2026 · By · Wire by Fusion42

Published

3 August 2026

Topic

regulatory

◆ Sectors

Health: Biotech

◆ Geography

United States

◆ Source

Read at survivornet.com →

◆ Verified

Fusion42 · 3 August 2026 · Fusion42 review

The FDA has approved Pluvicto for earlier treatment use in patients with PSMA-positive metastatic hormone-sensitive prostate cancer, expanding therapeutic options.

This Wire brief sits within Fusion42's coverage of Health: Biotech, and 2 sources have reported it between 1 Aug 2026 and 3 Aug 2026.

◆ ◆ The Wire takeaway

You can now target earlier-stage prostate cancer patients with PSMA-positive metastatic disease using Pluvicto, opening a new market stage for your therapeutic development.

◆ Coverage

2 sources · first reported 1 Aug 2026 · latest 3 Aug 2026

◆ Related on Wire

◆ Topics

Health: BiotechFDA-approvalprostate-cancerpluvictobiotechdrug-regulation